{ "instance": { "tlis-20211231.htm": { "axisCustom": 0, "axisStandard": 29, "contextCount": 217, "dts": { "calculationLink": { "local": [ "tlis-20211231_cal.xml" ] }, "definitionLink": { "local": [ "tlis-20211231_def.xml" ] }, "inline": { "local": [ "tlis-20211231.htm" ] }, "labelLink": { "local": [ "tlis-20211231_lab.xml" ] }, "presentationLink": { "local": [ "tlis-20211231_pre.xml" ] }, "schema": { "local": [ "tlis-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 612, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 2, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 6 }, "keyCustom": 88, "keyStandard": 364, "memberCustom": 43, "memberStandard": 35, "nsprefix": "tlis", "nsuri": "http://talisbio.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value Measurements", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Balance Sheet Components", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Grants Revenue and Receivable", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivable", "shortName": "Grants Revenue and Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Commitments and Contingencies", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stock-Based Compensation", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Related Party Transactions", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Income Taxes", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Net Loss Per Share", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Balance Sheets", "role": "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "lang": null, "name": "us-gaap:GrantsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Employee Benefit Plans", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans1", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Subsequent Events", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "tlis:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "tlis:PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Fair Value Measurements (Tables)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Balance Sheet Components (Tables)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "tlis:SummaryOfLeaseCostsAndSupplementalCashFlowInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "tlis:SummaryOfLeaseCostsAndSupplementalCashFlowInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "tlis:TemporaryEquityAndStockholdersEquityDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "tlis:TemporaryEquityAndStockholdersEquityDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Income Taxes (Tables)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTableTextBlock", "div", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Balance Sheets (Parenthetical)", "role": "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_7190f9eb-b2b1-412c-8522-57bea2e19afa", "decimals": "INF", "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Net Loss Per Share (Tables)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Organization and Nature of Business - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "shortName": "Organization and Nature of Business - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-5", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_3684c29d-7f0e-4b14-aa33-3dc0fc78a2e3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Summary of Significant Accounting Policies - Useful Lives of Assets (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails", "shortName": "Summary of Significant Accounting Policies - Useful Lives of Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_3684c29d-7f0e-4b14-aa33-3dc0fc78a2e3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Fair Value Measurements - Summary of Financial Assets Carried at Fair Value and Measured on Recurring Basis (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Financial Assets Carried at Fair Value and Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_5d4e949e-2a58-4699-bc65-a360c2da0ca0", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AssetsFairValueDisclosure", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "INF", "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Balance Sheet Components - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "shortName": "Balance Sheet Components - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Balance Sheet Components - Summary of Property and Equipment (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "shortName": "Balance Sheet Components - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "tlis:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails", "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "tlis:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DeferredRevenueDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_e008fdba-6674-4be9-95d6-32a290a49f74", "decimals": "-5", "first": true, "lang": null, "name": "tlis:InitialFundingReceived", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Grants Revenue and Receivable - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails", "shortName": "Grants Revenue and Receivable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DeferredRevenueDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_e008fdba-6674-4be9-95d6-32a290a49f74", "decimals": "-5", "first": true, "lang": null, "name": "tlis:InitialFundingReceived", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Statements of Operations and Comprehensive Loss", "role": "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss", "shortName": "Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_67ca50c8-3c58-48fb-8b0e-381a31f71ea0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_67ca50c8-3c58-48fb-8b0e-381a31f71ea0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:SummaryOfLeaseCostsAndSupplementalCashFlowInformationTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Supplemental Cash Flow Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails", "shortName": "Commitments and Contingencies - Summary of Lease Costs and Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:SummaryOfLeaseCostsAndSupplementalCashFlowInformationTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Commitments and Contingencies - Summary of Weighted-Average Remaining Lease Terms and Discount Rates (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails", "shortName": "Commitments and Contingencies - Summary of Weighted-Average Remaining Lease Terms and Discount Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Commitments and Contingencies - Schedule of Undiscounted Future Lease Payments (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails", "shortName": "Commitments and Contingencies - Schedule of Undiscounted Future Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_3a370358-d9f4-4496-a50e-f330fb64b5d2", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTableTextBlock", "div", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Convertible Preferred Stock (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTableTextBlock", "div", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ccf6c035-2be0-46d5-80b5-7a214bb5cf8f", "decimals": "INF", "lang": null, "name": "us-gaap:TemporaryEquityLiquidationPreference", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Instances (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Common Stock Reserved for Future Instances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "tlis:TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_263af8b4-f6ef-4244-877c-cba7977a8cfb", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails", "shortName": "Stock-Based Compensation - Summary of Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Stock-Based Compensation - Summary of Weighted-average Assumptions Used to Determine Grant Date Fair Value of Stock Options (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails", "shortName": "Stock-Based Compensation - Summary of Weighted-average Assumptions Used to Determine Grant Date Fair Value of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_1bcd0f35-dd9f-4e6d-96de-cbce36d6f239", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_1bcd0f35-dd9f-4e6d-96de-cbce36d6f239", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_cd3f977a-658b-4412-81c9-031d036353c6", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_cd3f977a-658b-4412-81c9-031d036353c6", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Stock-Based Compensation - Components of Stock-based Compensation Expense (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Components of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_71da310a-d203-4bc7-a0ab-89ee53aba632", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_263af8b4-f6ef-4244-877c-cba7977a8cfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6705ab46-ac4d-4eb0-8df8-6618121a00b1", "decimals": "-5", "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Rate Effective Tax (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails", "shortName": "Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Rate Effective Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Income Taxes - Significant Components of Deferred Income Taxes (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails", "shortName": "Income Taxes - Significant Components of Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_54a9408d-b942-4d2d-b554-614ced5eb9d6", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Income Taxes - Summary of NOLs and Tax Credit Carryforwards (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails", "shortName": "Income Taxes - Summary of NOLs and Tax Credit Carryforwards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "tlis:SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_54a9408d-b942-4d2d-b554-614ced5eb9d6", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Balance of Total Gross Unrecognized Tax Benefits (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Reconciliation of Beginning and Ending Balance of Total Gross Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_1bcd0f35-dd9f-4e6d-96de-cbce36d6f239", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_1b254a28-b0f6-4c20-a7fd-119ba78fde5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_1b254a28-b0f6-4c20-a7fd-119ba78fde5f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Employee Benefit Plans - Additional Information (Details)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails", "shortName": "Employee Benefit Plans - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_ff8d594a-ec5c-4a54-9780-1dd838a80ca4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Subsequent Event - Additional Information (Detail)", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail", "shortName": "Subsequent Event - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_41458da9-d167-4f61-b730-9368bb74378d", "decimals": "-5", "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Statements of Cash Flows", "role": "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Statements of Cash Flows (Parenthetical)", "role": "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_9c028d36-f26c-436a-aa4a-82d43db5cf80", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Organization and Nature of Business", "role": "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness", "shortName": "Organization and Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "tlis-20211231.htm", "contextRef": "C_6f5ec3b7-7fbf-41c8-9d54-89b2711f4e27", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 82, "tag": { "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r149", "r231", "r234", "r481" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r201", "r214", "r251", "r253", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r478", "r482", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r201", "r214", "r251", "r253", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r478", "r482", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r149", "r231", "r234", "r481" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r146", "r231", "r232", "r439", "r477", "r479" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r146", "r231", "r232", "r439", "r477", "r479" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r201", "r214", "r241", "r251", "r253", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r478", "r482", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r201", "r214", "r241", "r251", "r253", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r478", "r482", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r101", "r252" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r101", "r106", "r252" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r147", "r148", "r231", "r233", "r480", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r147", "r148", "r231", "r233", "r480", "r496", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r101", "r106", "r185", "r252", "r426" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r150", "r417" ], "lang": { "en-us": { "role": { "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redwood City, CA", "terseLabel": "Menlo Park, California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ILLINOIS", "terseLabel": "Chicago, IL" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_AccruedCompensationCurrent": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued compensation current", "label": "Accrued Compensation Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedCompensationCurrent", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "tlis_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development costs current.", "label": "Accrued Research And Development Costs Current", "terseLabel": "Accrued research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "tlis_AdditionalFundingAvailableUnderGrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional funding available under grant.", "label": "Additional funding available under grant" } } }, "localname": "AdditionalFundingAvailableUnderGrant", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_AdditionalFundingReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional funding received.", "label": "Additional Funding Received", "terseLabel": "Additional funding received" } } }, "localname": "AdditionalFundingReceived", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_AdditionalFundingYetToReceive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional Funding Yet to Receive", "label": "Additional Funding Yet To Receive", "terseLabel": "Additional funding" } } }, "localname": "AdditionalFundingYetToReceive", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_AggregateGrossProceedsFromRecapitalization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate gross proceeds from recapitalization.", "label": "Aggregate Gross Proceeds From Recapitalization", "terseLabel": "Gross proceeds from recapitalization" } } }, "localname": "AggregateGrossProceedsFromRecapitalization", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_CARBXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARB-X.", "label": "C A R B X [Member]", "terseLabel": "CARB-X" } } }, "localname": "CARBXMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_COVID19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19.", "label": "C O V I D19 [Member]", "terseLabel": "COVID-19" } } }, "localname": "COVID19Member", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_CancellationOfThirdTrancheConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cancellation of third tranche convertible preferred stock.", "label": "Cancellation Of Third Tranche Convertible Preferred Stock", "negatedLabel": "Cancellation of third tranche convertible preferred stock, Shares", "verboseLabel": "Cancellation of third tranche convertible preferred stock" } } }, "localname": "CancellationOfThirdTrancheConvertiblePreferredStock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "tlis_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tlis_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tlis_ConversionIntoCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion into common stock", "label": "Conversion Into Common Stock [Member]", "terseLabel": "Conversion Into Common Stock" } } }, "localname": "ConversionIntoCommonStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_ConversionIntoSeries2NonVotingConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion into series 2 non-voting convertible preferred stock.", "label": "Conversion Into Series2 Non Voting Convertible Preferred Stock [Member]", "terseLabel": "Conversion Into Series2 Non-voting Convertible Preferred Stock" } } }, "localname": "ConversionIntoSeries2NonVotingConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_ConvertiblePreferredStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock, conversion price per share.", "label": "Convertible Preferred Stock Conversion Price Per Share", "terseLabel": "Offering price of convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockConversionPricePerShare", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "tlis_ConvertiblePreferredStockConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock, conversion ratio.", "label": "Convertible Preferred Stock Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "ConvertiblePreferredStockConversionRatio", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "tlis_ConvertiblePreferredStockPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock.", "label": "Convertible Preferred Stock Policy [Text Block]", "terseLabel": "Historical Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockPolicyTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "tlis_CostIncurredDuringThePeriodForHighCapacityProduction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost incurred during the period for high capacity Production.", "label": "Cost Incurred During the Period for High Capacity Production", "terseLabel": "Cost incurred during the period for high capacity production" } } }, "localname": "CostIncurredDuringThePeriodForHighCapacityProduction", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_DeferredInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred initial public offering costs included in accounts payable and accrued expenses.", "label": "Deferred Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses", "terseLabel": "Deferred initial public offering costs included in accounts payable and accrued expenses" } } }, "localname": "DeferredInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tlis_DeferredTaxAssetsLeaseLiability": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets lease liability.", "label": "Deferred Tax Assets Lease Liability", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiability", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "tlis_DeferredTaxAssetsManufacturingLineAndProductionEquipment": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets manufacturing line and production equipment.", "label": "Deferred Tax Assets Manufacturing Line And Production Equipment", "terseLabel": "Manufacturing line and production equipment" } } }, "localname": "DeferredTaxAssetsManufacturingLineAndProductionEquipment", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "tlis_DeferredTaxAssetsOtherAccruals": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets other accruals.", "label": "Deferred Tax Assets Other Accruals", "terseLabel": "Other accruals" } } }, "localname": "DeferredTaxAssetsOtherAccruals", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "tlis_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities operating lease right of use asset.", "label": "Deferred Tax Liabilities Operating Lease Right Of Use Asset", "negatedLabel": "Operating lease right-of-use asset" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "tlis_DefinedContributionPlanAutomaticMatchingContributionBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined contribution plan automatic matching contribution basis.", "label": "Automatic matching contribution basis" } } }, "localname": "DefinedContributionPlanAutomaticMatchingContributionBasis", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tlis_DefinedContributionPlanEmployerMatchingContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined contribution plan, employer matching contribution, amount.", "label": "Defined Contribution Plan Employer Matching Contribution Amount", "terseLabel": "Matching contribution under this provision total" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionAmount", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_DefinedContributionPlanFirstAutomaticMatchingContributionPlanPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined contribution plan first automatic matching contribution plan percent.", "label": "First automatic matching contribution plan percent" } } }, "localname": "DefinedContributionPlanFirstAutomaticMatchingContributionPlanPercent", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_DefinedContributionPlanOnDollarAutomaticMatchingContributionPlanPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan On Dollar Automatic Matching Contribution Plan Percent", "label": "Dollar based automatic matching contribution plan percent" } } }, "localname": "DefinedContributionPlanOnDollarAutomaticMatchingContributionPlanPercent", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_EffectiveIncomeTaxRateReconciliationChangeInEstimatedFairValueRelatedToConvertibleNotes": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation change in estimated fair value related to convertible notes.", "label": "Effective Income Tax Rate Reconciliation Change In Estimated Fair Value Related To Convertible Notes", "terseLabel": "Change in estimated fair value related to convertible notes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEstimatedFairValueRelatedToConvertibleNotes", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "percentItemType" }, "tlis_EffectiveIncomeTaxRateReconciliationPermanentDeterrencePercentage": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation permanent deterrence percentage.", "label": "Effective Income Tax Rate Reconciliation Permanent Deterrence Percentage", "terseLabel": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentDeterrencePercentage", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "percentItemType" }, "tlis_EmergingGrowthCompanyStatusPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging growth company status policy.", "label": "Emerging Growth Company Status Policy Policy [Text Block]", "terseLabel": "Emerging Growth Company Status" } } }, "localname": "EmergingGrowthCompanyStatusPolicyPolicyTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "tlis_ExistingInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Existing investors.", "label": "Existing Investors [Member]", "terseLabel": "Existing Investors" } } }, "localname": "ExistingInvestorsMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_GrantRevenueAndReceivablesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant revenue and receivables policy.", "label": "Grant Revenue And Receivables Policy Policy [Text Block]", "terseLabel": "Grant Revenue and Receivables" } } }, "localname": "GrantRevenueAndReceivablesPolicyPolicyTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "tlis_GrantRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Grant revenue recognized.", "label": "Grant Revenue Recognized", "terseLabel": "Grant revenue recognized" } } }, "localname": "GrantRevenueRecognized", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_GrossProceedsFromIssueOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issue of shares.", "label": "Gross Proceeds From Issue Of Shares", "terseLabel": "Gross proceeds from issue of shares" } } }, "localname": "GrossProceedsFromIssueOfShares", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_HighCapacityProductionEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "High capacity production equipment.", "label": "High Capacity Production Equipment [Member]", "terseLabel": "High Capacity Production Equipment" } } }, "localname": "HighCapacityProductionEquipmentMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_IncreaseDecreaseInGrantsReceivable": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in grants receivable.", "label": "Increase Decrease In Grants Receivable", "negatedLabel": "Grants receivable" } } }, "localname": "IncreaseDecreaseInGrantsReceivable", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tlis_IncreaseDecreaseInLeaseLiabilitiesNet": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in lease liabilities net.", "label": "Increase Decrease In Lease Liabilities Net", "negatedLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilitiesNet", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tlis_IncreaseDecreaseInPrepaidResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in prepaid research and development.", "label": "Increase Decrease In Prepaid Research And Development", "negatedLabel": "Prepaid research and development" } } }, "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopment", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tlis_IncreaseInPercentageOfNumberOfIssuedAndOutstandingSharesOfCommonStockBeneficiallyOwnedByHolder": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in percentage of number of issued and outstanding shares of common stock beneficially owned by holder.", "label": "Increase In Percentage Of Number Of Issued And Outstanding Shares Of Common Stock Beneficially Owned By Holder", "terseLabel": "Increase in percentage of number of issued and outstanding shares of common stock beneficially owned by holder" } } }, "localname": "IncreaseInPercentageOfNumberOfIssuedAndOutstandingSharesOfCommonStockBeneficiallyOwnedByHolder", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_InitialFundingReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial funding received.", "label": "Initial Funding Received", "terseLabel": "Initial funding received" } } }, "localname": "InitialFundingReceived", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_InventoryPurchasesIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Inventory purchases included in accounts payable and accrued expenses", "label": "Inventory Purchases Included in Accounts Payable and Accrued Expenses", "terseLabel": "Inventory purchases included in accounts payable and accrued expenses" } } }, "localname": "InventoryPurchasesIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tlis_LaboratoryAndOfficeSpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory and office space.", "label": "Laboratory And Office Space [Member]", "terseLabel": "Laboratory and Office Space" } } }, "localname": "LaboratoryAndOfficeSpaceMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_LeaseExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration date.", "label": "Lease Expiration Date", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "tlis_LeaseExtendingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease extending date.", "label": "Lease Extending Date", "terseLabel": "Lease extending date" } } }, "localname": "LeaseExtendingDate", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "tlis_LesseeOperatingLeaseFixedEscalationsPercentagePerAnnum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease fixed escalations percentage per annum.", "label": "Lessee Operating Lease Fixed Escalations Percentage Per Annum", "terseLabel": "Fixed escalations percentage per annum" } } }, "localname": "LesseeOperatingLeaseFixedEscalationsPercentagePerAnnum", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_LesseeOperatingLeaseLeaseNotYetCommencedFixedEscalationsPercentagePerAnnum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease lease not yet commenced fixed escalations percentage per annum.", "label": "Lessee Operating Lease Lease Not Yet Commenced Fixed Escalations Percentage Per Annum", "terseLabel": "Fixed escalations percentage per annum" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedFixedEscalationsPercentagePerAnnum", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_LesseeOperatingLeaseLeaseNotYetCommencedMinimumCommitment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease lease not yet commenced, minimum commitment.", "label": "Lessee Operating Lease Lease Not Yet Commenced Minimum Commitment", "terseLabel": "Annual minimum commitment" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedMinimumCommitment", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_LesseeOperatingLeaseLeaseNotYetCommencedNumberOfOptionsToExtendLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease lease not yet commenced, number of options to extend Lease term.", "label": "Lessee Operating Lease Lease Not Yet Commenced Number Of Options To Extend Lease Term", "terseLabel": "Number of options to extend Lease term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedNumberOfOptionsToExtendLeaseTerm", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tlis_LesseeOperatingLeaseLeaseNotYetCommencedSecurityDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease lease not yet commenced security deposit.", "label": "Lessee Operating Lease Lease Not Yet Commenced Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedSecurityDeposit", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_LesseeOperatingLeaseMinimumCommitment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee, operating lease minimum commitment.", "label": "Lessee Operating Lease Minimum Commitment", "terseLabel": "Annual minimum commitment" } } }, "localname": "LesseeOperatingLeaseMinimumCommitment", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease number of options to extend lease term.", "label": "Lessee Operating Lease Number Of Options To Extend Lease Term", "terseLabel": "Number of options to extend Lease term" } } }, "localname": "LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "tlis_NIHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NIH.", "label": "N I H [Member]", "terseLabel": "NIH" } } }, "localname": "NIHMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_NetOperatingLossAndTaxCreditCarryforwardsUtilizationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss and tax credit carryforwards utilization period.", "label": "Net Operating Loss And Tax Credit Carryforwards Utilization Period", "terseLabel": "NOLs and tax credit carryforwards utilization period" } } }, "localname": "NetOperatingLossAndTaxCreditCarryforwardsUtilizationPeriod", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tlis_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash lease expense.", "label": "Noncash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tlis_NoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice period.", "label": "Notice Period", "terseLabel": "Notice period" } } }, "localname": "NoticePeriod", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "tlis_OfficeAndComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office and computer equipment.", "label": "Office And Computer Equipment [Member]", "terseLabel": "Office and Computer Equipment" } } }, "localname": "OfficeAndComputerEquipmentMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "tlis_OperatingLeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease commencement date.", "label": "Operating Lease Commencement Date", "terseLabel": "Operating lease commencement date" } } }, "localname": "OperatingLeaseCommencementDate", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "tlis_OperatingLeaseCommencementMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease commencement month and year.", "label": "Operating Lease Commencement Month And Year", "terseLabel": "Operating lease commencement month and year" } } }, "localname": "OperatingLeaseCommencementMonthAndYear", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "tlis_OperatingLossCarryforwardsEstimatedExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards estimated expiration year.", "label": "Operating Loss Carryforwards Estimated Expiration Year", "terseLabel": "NOLs, Expiration Years" } } }, "localname": "OperatingLossCarryforwardsEstimatedExpirationYear", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "tlis_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expiration year.", "label": "Operating Loss Carryforwards Expiration Year", "terseLabel": "NOLs, Expiration Years" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "gYearItemType" }, "tlis_OptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options to purchase common stock.", "label": "Options To Purchase Common Stock [Member]", "terseLabel": "Options to Purchase Common Stock" } } }, "localname": "OptionsToPurchaseCommonStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_OrganizationAndNatureOfBusinessLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization and nature of business.", "label": "Organization And Nature Of Business [Line Items]", "terseLabel": "Organization And Nature Of Business [Line Items]" } } }, "localname": "OrganizationAndNatureOfBusinessLineItems", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tlis_OrganizationAndNatureOfBusinessTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization and nature of business.", "label": "Organization And Nature Of Business [Table]", "terseLabel": "Organization And Nature Of Business [Table]" } } }, "localname": "OrganizationAndNatureOfBusinessTable", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tlis_PaymentToLandlord": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment to landlord.", "label": "Payment to Landlord", "terseLabel": "Payment to landlord for lease payments" } } }, "localname": "PaymentToLandlord", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_PendingIncomeTaxExamination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pending income tax examination.", "label": "Pending Income Tax Examination", "terseLabel": "Pending income tax examination" } } }, "localname": "PendingIncomeTaxExamination", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_PercentageOfEmployeesEligibleForDollarAutomaticMatchingContributionPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees eligible for dollar automatic matching contribution plan.", "label": "Percentage of employees eligible for dollar automatic matching contribution plan" } } }, "localname": "PercentageOfEmployeesEligibleForDollarAutomaticMatchingContributionPlan", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_PercentageOfNetOperatingLossAndTaxCreditCarryforwardsUtilizationSubjectToSubstantialAnnualLimitation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of net operating loss and tax credit carryforwards utilization subject to substantial annual limitation.", "label": "Percentage Of Net Operating Loss And Tax Credit Carryforwards Utilization Subject To Substantial Annual Limitation", "terseLabel": "Percentage of NOLs and tax credit carryforwards utilization subject to substantial annual limitation" } } }, "localname": "PercentageOfNetOperatingLossAndTaxCreditCarryforwardsUtilizationSubjectToSubstantialAnnualLimitation", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_PercentageOfNumberOfIssuedAndOutstandingSharesOfCommonStockBeneficiallyOwnedByHolder": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of number of issued and outstanding shares of common stock beneficially owned by holder.", "label": "Percentage Of Number Of Issued And Outstanding Shares Of Common Stock Beneficially Owned By Holder", "terseLabel": "Percentage of number of issued and outstanding shares of common stock beneficially owned by holder" } } }, "localname": "PercentageOfNumberOfIssuedAndOutstandingSharesOfCommonStockBeneficiallyOwnedByHolder", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_PercentageOfTaxBenefitRealizedUponUncertainResolutionOfContingency": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of tax benefit realized upon uncertain resolution of contingency", "label": "Percentage Of Tax Benefit Realized Upon Uncertain Resolution Of Contingency", "terseLabel": "Percentage of tax benefit realized upon uncertain resolution of contingency" } } }, "localname": "PercentageOfTaxBenefitRealizedUponUncertainResolutionOfContingency", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_PercentageOfVotingRightsHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of voting rights held.", "label": "Percentage Of Voting Rights Held", "terseLabel": "Percentage of voting rights" } } }, "localname": "PercentageOfVotingRightsHeld", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "tlis_PostDecemberTwoThousandSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Post December two thousand seventeen.", "label": "Post December Two Thousand Seventeen [Member]", "terseLabel": "Post December 31, 2017" } } }, "localname": "PostDecemberTwoThousandSeventeenMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "tlis_PotentialMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential milestone payment.", "label": "Potential Milestone Payment", "terseLabel": "Potential milestone payment" } } }, "localname": "PotentialMilestonePayment", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_PreLaunchInventoryRelatingToCartridges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Pre launch inventory relating to cartridges.", "label": "Pre Launch Inventory Relating To Cartridges", "terseLabel": "Pre launch inventory relating to cartridges" } } }, "localname": "PreLaunchInventoryRelatingToCartridges", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_PreLaunchInventoryToInstrumentComponentsResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Pre launch inventory to instrument components research and development expense.", "label": "Pre Launch Inventory to Instrument Components Research And Development Expense", "terseLabel": "Pre launch inventory to instrument components research and development expense" } } }, "localname": "PreLaunchInventoryToInstrumentComponentsResearchAndDevelopmentExpense", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_PrepaidResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research and development expenses.", "label": "Prepaid Research And Development Expenses", "terseLabel": "Prepaid research and development expenses" } } }, "localname": "PrepaidResearchAndDevelopmentExpenses", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "tlis_PreviousJanuaryFirstTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Previous January first two thousand eighteen.", "label": "Previous January First Two Thousand Eighteen [Member]", "terseLabel": "Pre January 1, 2018" } } }, "localname": "PreviousJanuaryFirstTwoThousandEighteenMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "tlis_ProceedsFromIssuanceOfSecondTrancheConvertiblePreferredStockNetOfIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of second tranche convertible preferred stock, net of issuance costs.", "label": "Proceeds From Issuance Of Second Tranche Convertible Preferred Stock Net Of Issuance Costs", "terseLabel": "Proceeds from second tranche convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfSecondTrancheConvertiblePreferredStockNetOfIssuanceCosts", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "tlis_ProductionEquipmentAcquiredNotToHaveAlternativeFutureUse": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Production equipment acquired not to have alternative future use.", "label": "Production Equipment Acquired Not To Have Alternative Future Use", "terseLabel": "Production equipment acquired not to have alternative future use" } } }, "localname": "ProductionEquipmentAcquiredNotToHaveAlternativeFutureUse", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_PropertyPlantAndEquipmentBeforeConstructionInprogress": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property plant and equipment before construction inprogress.", "label": "Property Plant And Equipment Before Construction Inprogress", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentBeforeConstructionInprogress", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "tlis_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property plant and equipment useful lives.", "label": "Property Plant and Equipment Useful Lives [Table Text Block]", "terseLabel": "Useful Lives of Assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "tlis_RADxInitiativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RADx initiative.", "label": "R A Dx Initiative [Member]", "terseLabel": "RADx Initiative" } } }, "localname": "RADxInitiativeMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_RADxInitiativePhaseTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RADx initiative phase two.", "label": "R A Dx Initiative Phase Two [Member]", "terseLabel": "RADx Initiative 2" } } }, "localname": "RADxInitiativePhaseTwoMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_ReclassificationsOfTemporaryEquityToPermanentEquityCommonStockAndSeriesOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassifications of temporary equity to permanent equity common stock and series one.", "label": "Reclassifications Of Temporary Equity To Permanent Equity Common Stock And Series One", "terseLabel": "Conversion of convertible preferred stock into common stock and Series 1 convertible preferred stock upon initial public offering" } } }, "localname": "ReclassificationsOfTemporaryEquityToPermanentEquityCommonStockAndSeriesOne", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "tlis_RedwoodCityCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redwood City, California.", "label": "Redwood City California [Member]", "terseLabel": "Redwood City, CA" } } }, "localname": "RedwoodCityCaliforniaMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_ReissuingStockOptionsExercisePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reissuing stock options exercise price per share.", "label": "Reissuing Stock Options Exercise Price Per Share", "terseLabel": "Reissuing stock options exercise price per share" } } }, "localname": "ReissuingStockOptionsExercisePricePerShare", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "tlis_RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModification": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remeasurement of operating lease right-of-use asset for lease modification.", "label": "Remeasurement Of Operating Lease Right Of Use Asset For Lease Modification", "terseLabel": "Remeasurement of operating lease right-of-use asset for lease modification" } } }, "localname": "RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModification", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "tlis_ResearchAndDevelopmentConsultingServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development consulting services.", "label": "Research and Development Consulting Services [Member]", "terseLabel": "Research And Development Consulting Services" } } }, "localname": "ResearchAndDevelopmentConsultingServicesMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_RevenueReceivedInCompletionOfFirstStage": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue Received in Completion of First Stage.", "label": "Revenue Received In Completion Of First Stage", "terseLabel": "Revenue received in completion of first stage" } } }, "localname": "RevenueReceivedInCompletionOfFirstStage", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_RevenueReceivedInCompletionOfSecondStage": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue Received in Completion of Second Stage.", "label": "Revenue Received In Completion Of Second Stage", "terseLabel": "Revenue received in completion of second stage" } } }, "localname": "RevenueReceivedInCompletionOfSecondStage", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_RightsOfferingPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rights offering purchased.", "label": "Rights Offering Purchased", "terseLabel": "Rights offering purchased" } } }, "localname": "RightsOfferingPurchased", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "tlis_ScheduleOfCashPaymentPerShareDueAndPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash payment per share due and payable.", "label": "Schedule Of Cash Payment Per Share Due And Payable Table [Text Block]", "terseLabel": "Schedule of Cash Payment per Share Due and Payable" } } }, "localname": "ScheduleOfCashPaymentPerShareDueAndPayableTableTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "tlis_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for future issuance", "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Common Stock Reserved for Future Instances" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "tlis_Series1ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series 1 convertible preferred stock.", "label": "Series1 Convertible Preferred Stock [Member]", "terseLabel": "Series 1 Convertible Preferred Stock" } } }, "localname": "Series1ConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "domainItemType" }, "tlis_SeriesC1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C -1 Preferred Stock.", "label": "Series C1 Preferred Stock [Member]", "terseLabel": "Series C-1 Preferred Stock" } } }, "localname": "SeriesC1PreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesCOneConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C-1 convertible preferred stock.", "label": "Series C One Convertible Preferred Stock [Member]", "terseLabel": "Series C-1 Convertible Preferred Stock" } } }, "localname": "SeriesCOneConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "tlis_SeriesCTwoConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C two convertible preferred stock.", "label": "Series C Two Convertible Preferred Stock [Member]", "terseLabel": "Series C-2 Convertible Preferred Stock" } } }, "localname": "SeriesCTwoConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesD1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D -1 Preferred Stock.", "label": "Series D1 Preferred Stock [Member]", "terseLabel": "Series D-1 Preferred Stock" } } }, "localname": "SeriesD1PreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesD2PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D -2 Preferred Stock.", "label": "Series D2 Preferred Stock [Member]", "terseLabel": "Series D-2 Preferred Stock" } } }, "localname": "SeriesD2PreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesDOneConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D-1 convertible preferred stock.", "label": "Series D One Convertible Preferred Stock [Member]", "terseLabel": "Series D-1 Convertible Preferred Stock" } } }, "localname": "SeriesDOneConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "tlis_SeriesDTwoConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D-2 convertible preferred stock.", "label": "Series D Two Convertible Preferred Stock [Member]", "terseLabel": "Series D-2 Convertible Preferred Stock" } } }, "localname": "SeriesDTwoConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "tlis_SeriesEOneConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E-1 convertible preferred stock.", "label": "Series E One Convertible Preferred Stock [Member]", "terseLabel": "Series E-1 Convertible Preferred Stock" } } }, "localname": "SeriesEOneConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "tlis_SeriesEOnePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E-1 preferred stock.", "label": "Series E One Preferred Stock [Member]", "terseLabel": "Series E-1 Preferred Stock" } } }, "localname": "SeriesEOnePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesETwoConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E-2 convertible preferred stock.", "label": "Series E Two Convertible Preferred Stock [Member]", "terseLabel": "Series E-2 Convertible Preferred Stock" } } }, "localname": "SeriesETwoConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "tlis_SeriesETwoPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E-2 preferred stock.", "label": "Series E Two Preferred Stock [Member]", "terseLabel": "Series E-2 Preferred Stock" } } }, "localname": "SeriesETwoPreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesF1ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F-1 convertible preferred stock.", "label": "Series F1 Convertible Preferred Stock [Member]", "terseLabel": "Series F-1 Convertible Preferred Stock" } } }, "localname": "SeriesF1ConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "tlis_SeriesF2ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F-2 convertible preferred stock.", "label": "Series F2 Convertible Preferred Stock [Member]", "terseLabel": "Series F-2 Convertible Preferred Stock" } } }, "localname": "SeriesF2ConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "tlis_SeriesFOneConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F-1 convertible preferred stock.", "label": "Series F One Convertible Preferred Stock [Member]", "terseLabel": "Series F-1 Convertible Preferred Stock" } } }, "localname": "SeriesFOneConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesFOnePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F-1 preferred stock.", "label": "Series F One Preferred Stock [Member]", "terseLabel": "Series F-1 Preferred Stock" } } }, "localname": "SeriesFOnePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesFTwoConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F-2 convertible preferred stock.", "label": "Series F Two Convertible Preferred Stock [Member]", "terseLabel": "Series F-2 convertible preferred stock" } } }, "localname": "SeriesFTwoConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesFTwoPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F-2 preferred stock.", "label": "Series F Two Preferred Stock [Member]", "terseLabel": "Series F-2 Preferred Stock" } } }, "localname": "SeriesFTwoPreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesOneConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series 1 convertible preferred stock.", "label": "Series One Convertible Preferred Stock [Member]", "terseLabel": "Series 1 Convertible Preferred Stock" } } }, "localname": "SeriesOneConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "domainItemType" }, "tlis_SeriesTwoConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series two convertible preferred stock.", "label": "Series Two Convertible Preferred Stock [Member]", "terseLabel": "Series 2" } } }, "localname": "SeriesTwoConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_SeriesTwoNonVotingConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series two non-voting convertible preferred stock.", "label": "Series Two Non Voting Convertible Preferred Stock [Member]", "terseLabel": "Series 2 Non-voting Convertible Preferred Stock" } } }, "localname": "SeriesTwoNonVotingConvertiblePreferredStockMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "tlis_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedFairValueOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, estimated fair value of common stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Estimated fair value of common stock", "terseLabel": "Estimated fair market value of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedFairValueOfCommonStock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "tlis_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, option, nonvested, weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Nonvested Weighted Average Remaining Contractual Term", "terseLabel": "Number of Units, Nonvested, Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageRemainingContractualTerm", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "tlis_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options, nonvested, intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value", "terseLabel": "Number of Units, Nonvested, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "tlis_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnexercisedExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangements by share-based payment award, options, unexercised, exercise price.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Unexercised, Exercise Price", "terseLabel": "Unexercised stock options, exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsUnexercisedExercisePrice", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "tlis_ShareBasedPaymentArrangementPlanModificationOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based payment arrangement plan modification options.", "label": "Share Based Payment Arrangement Plan Modification Options", "terseLabel": "Options accounted for as modification" } } }, "localname": "ShareBasedPaymentArrangementPlanModificationOptions", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "tlis_ShareBasedPaymentAwardOptionsGrantedInPeriodGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based payment award options granted in period grant date fair value.", "label": "Share Based Payment Award Options Granted In Period Grant Date Fair Value", "terseLabel": "Granted stock options with grant date fair value" } } }, "localname": "ShareBasedPaymentAwardOptionsGrantedInPeriodGrantDateFairValue", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_StockholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders.", "label": "Stockholders [Member]", "terseLabel": "Stockholders" } } }, "localname": "StockholdersMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_SummaryOfLeaseCostsAndSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of lease costs and supplemental cash flow information.", "label": "Summary Of Lease Costs And Supplemental Cash Flow Information Table [Text Block]", "terseLabel": "Summary of Lease Costs and Supplemental Cash Flow Information" } } }, "localname": "SummaryOfLeaseCostsAndSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "tlis_SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of operating loss and tax credit carryforwards.", "label": "Summary Of Operating Loss And Tax Credit Carryforwards Table [Text Block]", "terseLabel": "Summary of NOLs and Tax Credit Carryforwards" } } }, "localname": "SummaryOfOperatingLossAndTaxCreditCarryforwardsTableTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "tlis_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tlis_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "tlis_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of weighted average remaining lease terms and discount rates.", "label": "Summary Of Weighted Average Remaining Lease Terms And Discount Rates Table [Text Block]", "terseLabel": "Summary of Weighted Average Remaining Lease Terms and Discount Rates" } } }, "localname": "SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "tlis_TalisOneCartridgesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Talis one cartridges.", "label": "Talis One Cartridges [Member]", "terseLabel": "Talis One Cartridges" } } }, "localname": "TalisOneCartridgesMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_TaxCreditCarryforwardEstimatedExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforward estimated expiration year.", "label": "Tax Credit Carryforward Estimated Expiration Year", "terseLabel": "Tax credits, Expiration Years" } } }, "localname": "TaxCreditCarryforwardEstimatedExpirationYear", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "tlis_TaxCreditCarryforwardExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforward expiration year.", "label": "Tax Credit Carryforward Expiration Year", "terseLabel": "Tax credits, Expiration Years" } } }, "localname": "TaxCreditCarryforwardExpirationYear", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "gYearItemType" }, "tlis_TaxCreditsSubjectToLimitationsApplicableTaxReductionPerYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax credits subject to limitations applicable tax reduction per year.", "label": "Tax Credits Subject To Limitations Applicable Tax Reduction Per Year", "terseLabel": "Tax credits subject to limitations applicable tax reduction per year" } } }, "localname": "TaxCreditsSubjectToLimitationsApplicableTaxReductionPerYear", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_TaxableIncomeSubjectToLimitationForNetOperatingLossCarryforwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Taxable income subject to limitation for net operating loss carryforwards.", "label": "Taxable Income Subject To Limitation For Net Operating Loss Carryforwards", "terseLabel": "Taxable income subject to limitation for net operating loss carryforwards" } } }, "localname": "TaxableIncomeSubjectToLimitationForNetOperatingLossCarryforwards", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_TemporaryEquityAndStockholdersEquityDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity and stockholders' equity disclosure.", "label": "Temporary Equity And Stockholders Equity Disclosure Table [Text Block]", "terseLabel": "Schedule of Convertible Preferred Stock" } } }, "localname": "TemporaryEquityAndStockholdersEquityDisclosureTableTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "tlis_TemporaryEquityAndStockholdersEquityDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity and stockholders' equity disclosure.", "label": "Temporary Equity And Stockholders Equity Disclosure [Text Block]", "terseLabel": "Convertible Preferred Stock and Stockholders' Equity (Deficit)" } } }, "localname": "TemporaryEquityAndStockholdersEquityDisclosureTextBlock", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "tlis_TemporaryEquityAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity authorized amount.", "label": "Temporary Equity Authorized Amount", "terseLabel": "Aggregate investment amount" } } }, "localname": "TemporaryEquityAuthorizedAmount", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_TemporaryEquityPurchasePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity purchase price per share.", "label": "Temporary Equity Purchase Price Per Share", "terseLabel": "Purchase price per share" } } }, "localname": "TemporaryEquityPurchasePricePerShare", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "tlis_TemporaryEquityStockIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issuance cost.", "label": "Temporary Equity Stock Issuance Cost", "terseLabel": "Issuance cost" } } }, "localname": "TemporaryEquityStockIssuanceCost", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_TemporaryEquityStockIssuedDuringPeriodSharesCommonStockAndSeriesOneConversionOfConvertibleSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares common stock and series one conversion of convertible securities.", "label": "Temporary Equity Stock Issued During Period Shares Common Stock And Series One Conversion Of Convertible Securities", "terseLabel": "Temporary Equity, Conversion of convertible preferred stock into common stock and Series 1 convertible preferred stock upon initial public offering, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesCommonStockAndSeriesOneConversionOfConvertibleSecurities", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "tlis_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of convertible preferred stock, net of issuance costs, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "tlis_TermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of contract.", "label": "Term Of Contract", "terseLabel": "Term of contract" } } }, "localname": "TermOfContract", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "tlis_Termsandmilestoneconditionsoffinalthreestagesamount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "TermsAndMilestoneConditionsOfFinalThreeStagesAmount.", "label": "TermsAndMilestoneConditionsOfFinalThreeStagesAmount", "terseLabel": "Terms and milestone conditions of final three stages amount" } } }, "localname": "Termsandmilestoneconditionsoffinalthreestagesamount", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_Termsandmilestoneconditionsoffirsttwostagesamount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "TermsAndMilestoneConditionsOfFirstTwoStagesAmount.", "label": "TermsAndMilestoneConditionsOfFirstTwoStagesAmount", "terseLabel": "Terms and milestone conditions of first two stages amount" } } }, "localname": "Termsandmilestoneconditionsoffirsttwostagesamount", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "tlis_TwoThousandThirteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand thirteen equity incentive plan.", "label": "Two Thousand Thirteen Equity Incentive Plan [Member]", "terseLabel": "2013 Equity Incentive Plan" } } }, "localname": "TwoThousandThirteenEquityIncentivePlanMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 employee stock purchase plan.", "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase Plan", "verboseLabel": "2021 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "tlis_TwoThousandTwentyOneEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Equity Incentive Plan.", "label": "Two Thousand Twenty One Equity Incentive Plan [Member]", "terseLabel": "2021 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyOneEquityIncentivePlanMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "tlis_UnbilledGrantsReceivableCurrent": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unbilled grants receivable current.", "label": "Unbilled Grants Receivable Current", "terseLabel": "Unbilled grant receivables" } } }, "localname": "UnbilledGrantsReceivableCurrent", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "tlis_UnvestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock units.", "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested RSUs" } } }, "localname": "UnvestedRestrictedStockUnitsMember", "nsuri": "http://talisbio.com/20211231", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update201602 [Member]", "terseLabel": "ASU 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201815Member": { "auth_ref": [ "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).", "label": "Accounting Standards Update201815 [Member]", "terseLabel": "ASU 2018-15" } } }, "localname": "AccountingStandardsUpdate201815Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update202006 [Member]", "terseLabel": "ASU 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r41", "r423" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r175" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "tlis_PropertyPlantAndEquipmentBeforeConstructionInprogress", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r29" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r90", "r91", "r92", "r292", "r293", "r294", "r363" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r94", "r95", "r96", "r97", "r106", "r152", "r153", "r160", "r161", "r162", "r163", "r165", "r166", "r189", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r328", "r329", "r330", "r331", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r411", "r440", "r441", "r442", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r526", "r527", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r255", "r257", "r298", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r257", "r283", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from the computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r76", "r172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset impairment", "totalLabel": "Asset Impairment Charges, Total" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r132", "r140", "r144", "r155", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r343", "r347", "r376", "r421", "r423", "r456", "r467" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r53", "r86", "r155", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r343", "r347", "r376", "r421", "r423" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r366" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Total assets measured at fair value", "totalLabel": "Total assets measured at fair value", "verboseLabel": "Assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r258", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r36", "r78" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails": { "order": 0.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r16", "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r16", "r79", "r455" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r73", "r78", "r83" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalent and restricted cash at end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year", "totalLabel": "Total cash, cash equivalent and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows", "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r73", "r386" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCollateralForBorrowedSecurities": { "auth_ref": [ "r460", "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.", "label": "Cash Collateral For Borrowed Securities", "terseLabel": "Cash collateral for line of credit facility" } } }, "localname": "CashCollateralForBorrowedSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "terseLabel": "Cash equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Operating Activities Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r90", "r91", "r93", "r152", "r153", "r156", "r157", "r158", "r160", "r161", "r189", "r288", "r289", "r290", "r328", "r354", "r355", "r356", "r377", "r379", "r380", "r381", "r384", "r385", "r395", "r411", "r440", "r441", "r483", "r484", "r526" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change In Accounting Principle Accounting Standards Update Adopted", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r90", "r91", "r100", "r152", "r153", "r156", "r157", "r158", "r160", "r161", "r189", "r288", "r289", "r290", "r328", "r354", "r355", "r356", "r357", "r360", "r377", "r379", "r380", "r381", "r384", "r385", "r395", "r411", "r440", "r441", "r483", "r484", "r526" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change In Accounting Principle Accounting Standards Update Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": { "auth_ref": [ "r4", "r93", "r153", "r156", "r159", "r162", "r189", "r291", "r329", "r354", "r357", "r360", "r378", "r379", "r382", "r383", "r385", "r395", "r442", "r483", "r484", "r499" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was early adopted.", "label": "Change In Accounting Principle Accounting Standards Update Early Adoption", "terseLabel": "Change in accounting principle, accounting standards update, early adoption" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r94", "r105", "r154", "r164", "r295", "r332" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r84", "r86", "r107", "r108", "r109", "r111", "r113", "r119", "r120", "r121", "r155", "r190", "r194", "r195", "r196", "r199", "r200", "r211", "r212", "r216", "r217", "r376", "r522" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r46", "r184", "r461", "r473" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r181", "r182", "r183", "r186", "r498" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Class B Common Stock" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Shares reserved" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Common Stock Conversion Basis", "terseLabel": "Common stock, conversion basis" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r90", "r91", "r363" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares, issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r28", "r220" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares", "terseLabel": "Common stock, shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r28", "r423" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 200,000,000 and 230,000,000 shares authorized at December 31, 2021 and December 31, 2020, respectively; 26,408,031 and 2,126,254 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock Voting Rights", "terseLabel": "Common stock, voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r239", "r240", "r254", "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation And Employee Benefit Plans [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlans1" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Deferred Tax Assets And Liabilities [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r124", "r465" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r174" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress Gross", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r80", "r81", "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion Of Stock Amount Converted1", "terseLabel": "Conversion of Stock, Amount Converted" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r80", "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Information by description of stock conversions.", "label": "Conversion Of Stock By Unique Description [Axis]", "terseLabel": "Stock Conversion Description" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r80", "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion Of Stock Name [Domain]", "terseLabel": "Conversion of Stock, Name" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r80", "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion Of Stock Shares Converted1", "terseLabel": "Shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r211", "r212", "r216" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock", "verboseLabel": "Historical Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r26", "r27", "r218", "r221", "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Common shares issuable upon conversion", "terseLabel": "Shares issued on conversion of convertible preferred shares" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges Policy [Text Block]", "terseLabel": "Deferred Initial Public Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r22", "r23", "r316", "r457", "r466" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities", "terseLabel": "Total deferred tax liabilities", "totalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r52", "r167" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueDisclosureTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue Disclosure [Text Block]", "terseLabel": "Grants Revenue and Receivable" } } }, "localname": "DeferredRevenueDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r317" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total gross deferred tax asset" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r324", "r325" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets Inventory", "terseLabel": "Inventory related costs" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r319" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r319" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r324", "r325" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Federal and state operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r322", "r324", "r325" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research", "terseLabel": "Research and development tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r324", "r325" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Compensation related items", "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r318" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r324", "r325" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan Employer Discretionary Contribution Amount", "terseLabel": "Discretionary contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Employer matching contribution maximum percent of match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent", "terseLabel": "Employee\u2019s contributions, up to a maximum company percentage" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r76", "r173" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r76", "r173" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of defined contribution pension and other postretirement plans.", "label": "Description Of Defined Contribution Pension And Other Postretirement Plans", "terseLabel": "Defined contribution plan, description" } } }, "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r20", "r21", "r458", "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable Current And Noncurrent", "terseLabel": "Preferred stock dividend declared or accrued" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share, basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r114", "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r306" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Total provision for income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]", "terseLabel": "Effective income tax rate:" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r87", "r306", "r335" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Expected income tax benefit at the federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r306", "r335" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r306", "r335" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r306", "r335" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation Tax Credits", "terseLabel": "Permanent differences", "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r306", "r335" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation Tax Credits Research", "terseLabel": "Research and development tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateEffectiveTaxDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized stock-based compensation expense related to stock option", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Expected weighted-average period for recognition of compensation expense related" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized compensation expense related to stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Options", "verboseLabel": "Options to Purchase Common Stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Lab Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r58", "r59", "r60", "r90", "r91", "r92", "r95", "r102", "r104", "r118", "r163", "r220", "r228", "r292", "r293", "r294", "r330", "r331", "r363", "r387", "r388", "r389", "r390", "r391", "r392", "r485", "r486", "r487", "r530" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r366", "r367", "r368", "r374" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Assets Level1 To Level2 Transfers Amount", "terseLabel": "Fair value, assets transfers from level 1 to level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Assets Level2 To Level1 Transfers Amount", "terseLabel": "Fair value, assets transfers from level 2 to level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Summary of Financial Assets Carried at Fair Value and Measured on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r366", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r202", "r204", "r205", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r367", "r428", "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r366", "r367", "r369", "r370", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r202", "r242", "r243", "r248", "r250", "r367", "r428" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r202", "r204", "r205", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r367", "r430" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount", "terseLabel": "Fair value, liabilities transfers from level 1 to level 2" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount", "terseLabel": "Fair value, liabilities transfers from level 2 to level 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "auth_ref": [ "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3", "terseLabel": "Fair value, Liabilities, transfers into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3", "terseLabel": "Fair value, Liabilities, transfers out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3", "terseLabel": "Fair value, assets transfers into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3", "terseLabel": "Fair value, assets transfers out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r202", "r204", "r205", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r428", "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r373", "r375" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FundsHeldForClients": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the funds held on behalf of others and that are expected to be liquidated within one year or the normal operating cycle, if longer. This does not include funds held under reinsurance agreements.", "label": "Funds Held For Clients", "terseLabel": "Funds held as long-term deposit" } } }, "localname": "FundsHeldForClients", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantsReceivableCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Grants Receivable Current", "terseLabel": "Grant receivables" } } }, "localname": "GrantsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r170", "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r177", "r179" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r87", "r307", "r314", "r321", "r333", "r336", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r88", "r103", "r104", "r131", "r305", "r334", "r337", "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Income tax expense", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r57", "r303", "r304", "r314", "r315", "r320", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r75" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r75" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase Decrease In Other Noncurrent Assets", "negatedLabel": "Other long term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r75" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r51", "r423" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventory", "totalLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r408", "r410" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "totalLabel": "Total operating lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Cost [Abstract]", "terseLabel": "Lease Costs" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Existence of option to extend operating lease" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced.", "label": "Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Extend", "terseLabel": "Existence of option to extend operating lease" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Lease Not Yet Commenced Renewal Term1", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1", "terseLabel": "Initial term of operating lease" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Undiscounted Future Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r409" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r409" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "2027 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r409" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r409" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r409" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r409" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r409" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r409" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Initial term of operating lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter Of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r86", "r141", "r155", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r344", "r347", "r348", "r376", "r421", "r422" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r86", "r155", "r376", "r423", "r459", "r471" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities, convertible preferred stock and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r86", "r155", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r344", "r347", "r348", "r376", "r421", "r422", "r423" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "terseLabel": "Liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "letter of credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsCarriedAtFairValueAndMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r73" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r73", "r74", "r77" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r55", "r56", "r60", "r62", "r77", "r86", "r94", "r98", "r99", "r100", "r101", "r103", "r104", "r110", "r132", "r139", "r142", "r143", "r145", "r155", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r365", "r376", "r462", "r475" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss and comprehensive loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of noncash activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": { "auth_ref": [ "r80", "r81", "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Value Of Assets Acquired1", "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses", "totalLabel": "Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r132", "r139", "r142", "r143", "r145" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r402", "r410" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r397" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r397" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails2": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "negatedLabel": "Less: current portion of lease liabilities", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r397" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails2": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities, long-term portion", "totalLabel": "Operating Lease Liability Noncurrent, Total" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfUndiscountedFutureLeasePaymentsDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r398", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Operating cash flows used for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r396" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use-assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r407", "r410" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r406", "r410" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "NOLs, Amount", "totalLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r7", "r351" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other long-term assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r44", "r423" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities Current", "terseLabel": "Other liabilities", "totalLabel": "Other Liabilities, Current, Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other income (expense), net", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Underwriter's Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "auth_ref": [ "r69" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.", "label": "Payments For Repurchase Of Initial Public Offering", "negatedLabel": "Payment of deferred initial public offering costs" } } }, "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "terseLabel": "Stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchase of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r258", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock Convertible Conversion Price", "terseLabel": "Convertible preferred stock, conversion price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r27", "r84", "r216", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock Liquidation Preference", "terseLabel": "Preferred stock liquidation preference" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r84", "r216" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred Stock Liquidation Preference Value", "terseLabel": "Preferred stock, aggregate liquidation preference" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r27", "r211" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock No Par Value", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r27", "r211" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock value per share", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r27", "r211" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred shares issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred shares outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r27", "r423" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Series 1 convertible preferred stock, $0.0001 par value-60,000,000 and 57,324,227 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 29,863,674 and no shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively; aggregate liquidation preference of $3 as of December 31, 2021 and none as of December 31, 2020", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r34", "r35" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Member]", "terseLabel": "Prepaid And Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Prior Period Reclassification Adjustment Description", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuance Initial Public Offering", "terseLabel": "Proceeds received from IPO" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from initial public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds From Issuance Of Convertible Preferred Stock", "terseLabel": "Proceeds from the issuance of convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r67" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock", "terseLabel": "Proceeds from the issuance of convertible preferred stock, net of issuance costs", "verboseLabel": "Proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds From Long Term Lines Of Credit", "terseLabel": "Proceeds from long-term lines of credit" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r67", "r287" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r67" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds From Stock Plans", "terseLabel": "Proceeds from stock issuances pursuant to employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r55", "r56", "r60", "r72", "r86", "r94", "r103", "r104", "r132", "r139", "r142", "r143", "r145", "r155", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r342", "r345", "r346", "r349", "r350", "r365", "r376", "r463" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r39", "r176" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property Plant And Equipment Estimated Useful Lives", "terseLabel": "Estimated Useful Life (in years)" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r38", "r174" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails": { "order": 0.0, "parentTag": "tlis_PropertyPlantAndEquipmentBeforeConstructionInprogress", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r176", "r423", "r464", "r472" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r37", "r176", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r176" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Useful Lives of Assets", "verboseLabel": "Summary of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r174" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Estimated Useful Life (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Unconditional purchase obligation", "totalLabel": "Purchase Obligation, Total" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r249", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r249", "r414", "r415", "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r414" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction Expenses From Transactions With Related Party", "terseLabel": "Payments to related party for services received" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r249", "r414", "r418", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r412", "r413", "r415", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r70", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments Of Lines Of Credit", "terseLabel": "Payment to contract manufacturing organization" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r301", "r438", "r513" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research [Member]", "terseLabel": "Research and Development Tax Credits" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r83", "r455", "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r8", "r16", "r83" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Operating lease, held as restricted cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r12", "r19", "r83", "r497" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash - other long term assets" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Unit" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r228", "r295", "r423", "r470", "r489", "r494" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r90", "r91", "r92", "r95", "r102", "r104", "r163", "r292", "r293", "r294", "r330", "r331", "r363", "r485", "r487" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r61" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not From Contract With Customer", "terseLabel": "Grant revenue" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r405", "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Significant Components of Deferred Income Taxes" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Computation of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Statutory Federal Income Tax Rate Effective Tax" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r257", "r282", "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r257", "r282", "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Components of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r39", "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r416", "r418" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r258", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r261", "r272", "r274" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Summary of Weighted-average Assumptions Used to Determine Grant Date Fair Value of Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r47", "r84", "r119", "r120", "r206", "r209", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r219", "r221", "r222", "r223", "r225", "r226", "r227", "r228" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r313", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]", "terseLabel": "Reconciliation of Beginning and Ending Balance of Total Gross Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r133", "r134", "r135", "r136", "r137", "r138", "r147" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationComponentsOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Expense related to reduction in force expects to recognize" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r75" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Granted", "verboseLabel": "Equity awards granted during period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Outstanding at December 31, 2021", "periodStartLabel": "Outstanding at December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at December 31, 2021", "periodStartLabel": "Outstanding at December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "terseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate", "terseLabel": "Maximum percentage of gross compensation to be invested by employees through payroll deductions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The highest quantity of shares an employee can purchase under the plan per period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee", "terseLabel": "Maximum number of shares an employee may purchase" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Number of Units, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Number of Units, Exercisable, Weighted Average Exercise Price per Unit" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of Units, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Units, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of Units, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value per share for options granted", "verboseLabel": "Granted stock options with grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Number of Units Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r263", "r286" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of Units Outstanding, Ending Balance", "periodStartLabel": "Number of Units Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Number of Units Outstanding, Weighted Average Exercise Price per Unit, Ending Balance", "periodStartLabel": "Number of Units Outstanding, Weighted Average Exercise Price per Unit, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r256", "r286" ], "lang": { "en-us": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased", "terseLabel": "Share-based compensation, weighted average exercise price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost", "terseLabel": "Incremental expense recorded for modification" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period", "terseLabel": "Number of shares issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r256", "r286" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award", "terseLabel": "Purchase of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r256", "r259" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Number of Units, Exercised, Weighted Average Exercise Price per Unit" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Number of Units, Expired, Weighted Average Exercise Price per Unit" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Number of Units, Forfeited, Weighted Average Exercise Price per Unit" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Number of Units, Granted, Weighted Average Exercise Price per Unit" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche One [Member]", "terseLabel": "First Tranche" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Three [Member]", "terseLabel": "Third Tranche" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Two [Member]", "terseLabel": "Share-based Payment Arrangement, Tranche Two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r258", "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Purchase price", "verboseLabel": "Cash payment per share due and payable" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r277", "r296" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedaverageAssumptionsUsedToDetermineGrantDateFairValueOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Number of Units, Exercisable, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Number of Units, Exercisable, Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "terseLabel": "Number of Units, Nonvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance", "terseLabel": "Number of Units, Nonvested, Weighted Average Exercise Price per Unit" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Number of Units Outstanding, Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Purchase price of common stock, as a percentage of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r187", "r188", "r341", "r495" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters Of Credit [Member]", "terseLabel": "Standby Letters of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r26", "r27", "r28", "r84", "r86", "r107", "r108", "r109", "r111", "r113", "r119", "r120", "r121", "r155", "r190", "r194", "r195", "r196", "r199", "r200", "r211", "r212", "r216", "r217", "r220", "r376", "r522" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCommonStockReservedForFutureInstancesDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r50", "r58", "r59", "r60", "r90", "r91", "r92", "r95", "r102", "r104", "r118", "r163", "r220", "r228", "r292", "r293", "r294", "r330", "r331", "r363", "r387", "r388", "r389", "r390", "r391", "r392", "r485", "r486", "r487", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r90", "r91", "r92", "r118", "r439" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r49", "r203", "r220", "r221", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Preferred shares converted" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r27", "r28", "r220", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of Common Stock pursuant to employee stock purchase plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r27", "r28", "r220", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of Common Stock upon initial public offering, net of issuance costs, Shares", "verboseLabel": "Common stock issued and sold" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r27", "r28", "r220", "r228", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Number of Units, Exercised", "terseLabel": "Issuance of Common Stock upon exercise of stock options, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivityDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r27", "r28", "r220", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of Common Stock pursuant to employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r27", "r28", "r220", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of Common Stock upon initial public offering, net of issuance costs of $21,349" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r50", "r220", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of Common Stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r28", "r31", "r32", "r86", "r151", "r155", "r376", "r423" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": { "auth_ref": [ "r24", "r25", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.", "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]", "terseLabel": "Preferred Stock" } } }, "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders Equity Note Stock Split Conversion Ratio1", "terseLabel": "Reverse stock split, conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r393", "r425" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r393", "r425" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r393", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r393", "r425" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r424", "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Tax credits, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfNolsAndTaxCreditCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r190", "r194", "r195", "r196", "r199", "r200" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying value", "periodEndLabel": "Temporary Equity Balance", "periodStartLabel": "Temporary Equity Balance", "terseLabel": "Convertible preferred stock, $0.0001 par value-no shares authorized as of December 31, 2021 and 229,296,908 shares authorized as of December 31, 2020; no shares issued and outstanding as of December 31, 2021 and 53,509,351 shares issued and outstanding as of December 31, 2020; no aggregate liquidation preference as of December 31, 2021 and $475,617 as of December 31, 2020", "verboseLabel": "Carrying value" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheets", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Convertible preferred stock, aggregate liquidation preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r15", "r207" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity Par Or Stated Value Per Share", "terseLabel": "Convertible preferred stock, par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, preferred authorized", "terseLabel": "Convertible preferred stock, shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, preferred shares issued", "terseLabel": "Convertible preferred stock, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, preferred shares outstanding", "periodEndLabel": "Temporary Equity Balance, Shares", "periodStartLabel": "Temporary Equity Balance, Shares", "terseLabel": "Convertible preferred stock, shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfConvertiblePreferredStockDetails", "http://talisbio.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity Stock Issued During Period Value New Issues", "terseLabel": "Issuance of convertible preferred stock, net of issuance costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r94", "r95", "r96", "r97", "r106", "r152", "r153", "r160", "r161", "r162", "r163", "r165", "r166", "r189", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r328", "r329", "r330", "r331", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r411", "r440", "r441", "r442", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r526", "r527", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnbilledReceivablesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.", "label": "Unbilled Receivables Current", "terseLabel": "Unbilled receivables" } } }, "localname": "UnbilledReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureGrantsRevenueAndReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r302", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits at the end of the period", "periodStartLabel": "Unrecognized tax benefits at the beginning of the period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions", "negatedLabel": "Changes for previous tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense", "terseLabel": "Interest and penalties associated with unrecognized tax benefits", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Additions for current tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingBalanceOfTotalGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk Or Uncertainty By Nature [Axis]", "terseLabel": "Unusual Risk or Uncertainty, Nature" } } }, "localname": "UnusualRiskOrUncertaintyByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualRiskOrUncertaintyNatureDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.", "label": "Unusual Risk Or Uncertainty Nature [Domain]", "terseLabel": "Unusual Risk or Uncertainty, Nature" } } }, "localname": "UnusualRiskOrUncertaintyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r122", "r123", "r125", "r126", "r127", "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "terseLabel": "Valuation allowance increased" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r403", "r410" ], "calculation": { "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://talisbio.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfCashPaymentPerShareDueAndPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average shares used in the calculation of net loss per share, basic and diluted:" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "http://talisbio.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://talisbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "430", "URI": "http://asc.fasb.org/topic&trid=2122452" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467743&loc=d3e20905-112640" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r427": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.1)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=123877278&loc=SL120174030-210619" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r514": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r515": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r516": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r517": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r518": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r519": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r521": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r522": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r523": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r524": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r525": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" } }, "version": "2.1" }